文献速递骨质疏松与代谢性骨病

罗莫佐单抗与特立帕肽对骨质疏松患者痴呆风险的目标试验模拟研究

Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study.
PubMed 文献 · Osteoporos Int · 2026-04-17

该目标试验模拟研究利用日本69,543例骨质疏松患者的纵向理赔数据,比较罗莫佐单抗与特立帕肽新使用者痴呆发生风险。2年意向性分析中罗莫佐单抗组痴呆绝对风险降低0.7%(95%CI -0.1至1.3%),相对风险0.91(95%CI 0.84至1.01);1年符合方案分析中绝对风险降低1.0%(95%CI 0.7至1.4%),相对风险0.76(95%CI 0.69至0.82)。结论提示罗莫佐单抗起始可能与比特立帕肽起始更低的痴呆风险相关,尤其阿尔茨海默病。

要点

  • 罗莫佐单抗起始者2年痴呆风险与特立帕肽无显著差异,RR 0.91(95%CI 0.84至1.01)。
  • 1年符合方案分析中罗莫佐单抗组痴呆风险显著更低,RR 0.76(95%CI 0.69至0.82)。
  • 阿尔茨海默病风险在1年符合方案分析中RR 0.77(95%CI 0.65至0.86)。

核心结论

  • 骨质疏松患者中,罗莫佐单抗起始可能与比特立帕肽起始更低的痴呆风险相关,尤其阿尔茨海默病。

研究设计与样本

  • 采用日本纵向商业理赔数据模拟目标试验,纳入2019至2023年新起始罗莫佐单抗或特立帕肽的50岁及以上骨质疏松患者69,543例,90%为女性,平均年龄81岁。

主要发现

  • 2年意向性分析中,痴呆绝对风险降低0.7%(95%CI -0.1至1.3%),相对风险0.91(95%CI 0.84至1.01)。
  • 2年意向性分析中,阿尔茨海默病绝对风险降低0.6%(95%CI 0.0至1.1%),相对风险0.88(95%CI 0.79至1.00)。
  • 1年符合方案分析中,痴呆绝对风险降低1.0%(95%CI 0.7至1.4%),相对风险0.76(95%CI 0.69至0.82)。
  • 1年符合方案分析中,阿尔茨海默病绝对风险降低0.6%(95%CI 0.3至0.9%),相对风险0.77(95%CI 0.65至0.86)。

关键数值与推荐

  • 主要结局为痴呆发生率,次要结局为阿尔茨海默病;采用加权Kaplan-Meier估计绝对风险降低和相对风险,并进行意向性治疗和符合方案分析。

临床怎么用

  • 对骨质疏松患者选择罗莫佐单抗或特立帕肽时,可将痴呆风险作为潜在考量因素,但需结合患者个体情况并注意证据来自观察性模拟研究。

局限性

  • 本研究为目标试验模拟研究,基于理赔数据,可能存在未测量混杂,且原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This target-trial emulation study sought to assess the association between romosozumab and incident dementia. We analyzed longitudinal claims data from 69,543 Japanese individuals with osteoporosis (using teriparatide as an active comparator), finding that romosozumab initiation among individuals with osteoporosis may correlate with a lower dementia risk than teriparatide initiation. PURPOSE: The neurocognitive benefits of osteoporosis treatments remain underexplored despite growing interest in the bone-brain connection. We aimed to analyze the association between romosozumab and incident dementia, using teriparatide as the active comparator. METHODS: We emulated a target trial using longitudinal commercial claims data from Japan. We identified individuals aged ≥ 50 years with osteoporosis who newly initiated either romosozumab or teriparatide between 2019 and 2023. The primary outcome was incident dementia, and the secondary outcome was Alzheimer's disease. We estimated the absolute risk reduction (ARR) and relative risk (RR) using a weighted Kaplan-Meier estimator, conducting both intention-to-treat and per-protocol analyses. RESULTS: A total of 69,543 individuals were included in the study (90% female; mean age, 81 years). In the 2-year intention-to-treat analyses, the ARR was 0.7% (95% confidence interval, - 0.1 to 1.3%), with a RR of 0.91 (95% confidence interval, 0.84 to 1.01). For Alzheimer's disease specifically, the ARR was 0.6% (95% confidence interval, 0.0 to 1.1%), with an RR of 0.88 (95% confidence interval, 0.79 to 1.00). In the 1-year per-protocol analyses, the ARR was 1.0% (95% confidence interval, 0.7 to 1.4%), with a RR of 0.76 (95% confidence interval, 0.69 to 0.82). For Alzheimer's disease specifically, the ARR was 0.6% (95% confidence interval, 0.3 to 0.9%), with an RR of 0.77 (95% confidence interval, 0.65 to 0.86). CONCLUSIONS: In this target trial emulation study, romosozumab initiation among individuals with osteoporosis may be associated with a lower risk of dementia, particularly Alzheimer's disease, than teriparatide initiation.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Hatano M, Okada A, Sasabuchi Y, et al. Romosozumab versus teriparatide for risk of dementia in individuals with osteoporosis: a target trial emulation study. Osteoporos Int. 2026. PMID: 41995806. doi:10.1007/s00198-026-08026-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。